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Summary
Oligosaccharides represent a significant fraction of breast
milk, reaching up to 20 g/l in early milk. Human milk oli-
gosaccharides comprise close to 200 structures, which are
not absorbed by the intestinal tissue and have no nutrition-
al value for the breastfed infant. Early studies conducted
around 1930 already attributed a prebiotic activity to milk
oligosaccharides by showing their stimulatory effects on
the growth of specific intestinal microbiota. In addition,
milk oligosaccharides contribute to the defence against en-
teric pathogens by acting as soluble decoys preventing the
adhesion of viruses and bacteria to their carbohydrate mu-
cosal receptors. The structural complexity of milk oligosac-
charides hampers the assignment of specific functions to
single carbohydrates. The application of mouse models al-
lows the investigation of unique milk oligosaccharides in
the context of intestinal microbiota and mucosal immunity.
In this respect, our recent work has demonstrated that up-
take of the milk oligosaccharide 3-sialyllactose increases
the inflammatory response observed in different colitis
models. The proinflammatory action of 3-sialyllactose was
attributed on the one hand to the modulation of intestinal
bacterial groups, and on the other hand to a direct stimu-
latory effect on CD11c+ dendritic cells. The availability of
pure oligosaccharides in large amounts will soon enable the
study of these compounds in humans in the context of in-
testinal and metabolic disorders associated to various forms
of dysbiosis.
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Article
Got breast milk? If so, was it worth it? While the first ques-
tion paraphrases the tagline of a successful advertisement
campaign for milk, the second one is more pertinent to the
debated benefits of breast milk. The protective effect of
breast milk was first recognised at the beginning of the 20th
century after studies recorded that infantile mortality was
seven times higher in formula-fed babies when compared
with breast-fed babies [1]. Nowadays, despite the tremend-
ous progress achieved in paediatric medicine, formula-fed
infants still have a five- to ten-fold increased risk compared
with breast-fed infants of developing necrotising entero-
colitis [2], which affects about 5% of premature infants
with a birth weight below 1,500 g [3].
The composition of breast milk has been extensively in-
vestigated, thereby unravelling a tremendous structural
complexity; yet the mechanisms underlying the protective
effects of breast milk are still not fully elucidated. When
considering the main classes of molecules, breast milk is
somewhat similar to cow’s milk (fig. 1A). A closer exam-
ination, however, shows profound differences that account
for the distinct digestive properties and protective functions
of both fluids. For example, casein represents 80% of the
protein in cow’s milk, and is acid insoluble and difficult
to process by the infant digestive system [4]. In contrast,
breast milk is rich in protective proteins such as immun-
oglobulin IgA, and the antimicrobial proteins lysozyme
and lactoferrin (fig. 1B). The carbohydrate fraction also
dramatically differs between breast milk and cow’s milk.
Whereas cow’s milk contains about 40 g/l of lactose and
only traces of larger oligosaccharides, breast milk contains
50–70 g/l of lactose plus 5–10 g/l of complex oligosacchar-
ides [5], with oligosaccharide concentrations reaching up to
20 g/l in colostrum [6]. Approximately 200 molecular spe-
cies of milk oligosaccharides have been identified, based
Figure 1
Composition of breast milk and cow’s milk. (A) General molecular
classes given in percent of total mass. (B) Percentage of main
types of milk proteins.
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on the extension of lactose [7], which is a disaccharide
combining galactose (Gal) and glucose (Glc) and represen-
ted as Gal(β1–4)Glc. Multiple glycosyltransferase enzymes
expressed in the lactating mammary gland combine the car-
bohydrates Gal, Glc, fucose (Fuc), sialic acid (Sia), and
N-acetylglucosamine (GlcNAc) into linear and branched
oligosaccharide structures (fig. 2). The same glycosyltrans-
ferase enzymes are also expressed in most cell types, where
they contribute to the biosynthesis of glycolipids and gly-
coproteins [8]. Accordingly, milk oligosaccharides carry
epitopes found also in other bodily compartments such as
blood and the intestinal mucosa [9].
The structural diversity of milk oligosaccharides varies
from mother to mother and even varies during lactation
for each mother. The individual variability in glycosyl-
transferase expression affects both the quality and quantity
of milk oligosaccharides. For example, fucosyltransferase
genes determining blood group factors such as Lewis an-
tigens and secretor status will also affect the presence of
the corresponding fucosylated epitopes on milk oligosac-
charides (fig. 2) [10]. Colostrum and early milk are richest
in oligosaccharides, but the production of oligosaccharides
is maintained throughout lactation [11]. The structural ana-
lysis of milk oligosaccharides across the first weeks of
lactation showed that short structures such as tri- to pentas-
Figure 2
Milk oligosaccharide biosynthesis. Oligosaccharides are
represented by the symbolic nomenclature of the Functional
Consortium for Glycomics (see www.functionalglycomics.org).
The disaccharide lactose (in orange frame) is produced by the β1–4
galactosyltransferase / α-lactalbumin complex. Lactose is further
modified by elongation with galactose(β1–4)N-acetylglucosamine
disaccharides and addition of fucose and sialic acid.
2FL = fucosyl(α1,2)lactose; 3FL = fucosyl(α1,3)lactose; 3SL =
sialyl(α2,3)lactose; 6SL = sialyl(α2,6)lactose
accharides are mainly produced in the first weeks after par-
turition, whereas the amount of longer structures increases
Figure 3
Relative amount of two complex milk oligosaccharides during
lactation. The relative levels of the pentasaccharide lacto-N-
fucopentaose drop rapidly in the first week of lactation, whereas the
relative levels of the heptasaccharide lacto-N-fucoseptaose raise in
the first 2 weeks of lactation. Oligosaccharide levels are compared
with the constant levels of the milk tetrasaccharide lacto-N-tetraose.
The oligosaccharide levels shown were analysed in breast milk
samples collected from a single mother over 3 weeks after
childbirth.
Figure 4
Structure of 3–sialyllactose and 6–sialyllactose. The three-
dimensional structures point to the extended configuration of
3–sialyllactose and bent configuration of 6–sialyllactose. The
positions of the third and sixth C-atoms of galactose (Gal), to which
sialic acid (Sia) is attached are marked with the numbers 3 for
3–sialyllactose and 6 for 6–sialyllactose.
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over time (fig. 3). In contrast to other milk constituents like
fatty acids, milk oligosaccharides do not depend on the nu-
tritional status of the lactating mother. Rather, the changes
in milk oligosaccharide composition are controlled by ge-
netic mechanisms [12].
Milk oligosaccharides have no nutritional value for the
breastfed infant and these molecules tolerate the acidic
conditions of the upper gastrointestinal tract. In addition,
they are not cleaved in the intestine owing to the lack of
locally-expressed glycosidases [13]. Only a minor fraction
of milk oligosaccharides is absorbed and transferred to the
bloodstream, on the basis of the recovery of approxim-
ately 1% of ingested milk oligosaccharides in the urine of
suckling infants [14]. Milk oligosaccharides exert import-
ant prebiotic functions by promoting the colonisation of
the intestine by commensal microbiota. Recognition of the
role of milk oligosaccharides in shaping intestinal microbi-
ota dates back to the work of Schönfeld [15], who showed
that the previously described bifidus factor stimulating the
growth of bifidobacteria was in fact a carbohydrate fraction
specifically found in breast milk known as gynolactose
[16]. Gynolactose was later identified to be a mixture of
fucosylated tri- to penta-saccharides (fig. 2). Several fam-
ilies of bacteria such as Bifidobacteriaceae and Bacteroid-
aceae express glycosidase enzymes that are able to cleave
milk oligosaccharides and use the resulting monosacchar-
ides as a carbon source [17]. These released monosacchar-
ides can also be assimilated by bacteria lacking dedicated
glycosidases, as in the case of Enterobacteriaceae, thereby
complicating the detection of associations between specific
milk oligosaccharides and intestinal microbiota [18].
Through their structural similarity to cellular glycans, milk
oligosaccharides also act as soluble receptors for several
bacteria and viruses. In 1956, the biochemists Kuhn and
Brossmer attributed the inhibitory effect of breast milk on
influenza virus to sialylated milk oligosaccharides, which
mimicked the cellular receptors for that virus [19]. Fu-
cosylated milk oligosaccharides also bind to several strains
of norovirus, thereby preventing the docking of the virus to
cellular glycan receptors [20] and hence the development
of acute gastroenteritis. The neutralising effect of milk oli-
gosaccharides is not limited to viruses. Milk oligosacchar-
ides also inhibit the adhesion of multiple bacteria such as
Campylobacter jejuni [21], Listeria monocytogenes [22]
and Streptococcus pneumonia [23] to the intestinal epithe-
lium. Furthermore, milk oligosaccharides protect against
bacterial enterotoxins such as cholera toxin [24] by com-
peting with cell-bound glycan receptors.
Soluble oligosaccharides and cell-surface bound glycans
also interact with leucocytes, which express carbohydrate-
binding proteins called lectins. These lectins function in the
context of the innate immune system by recognising for-
eign carbohydrate antigens, but they also regulate leuco-
cyte activation through the binding of specific cell-surface
glycans. The recognition of mycobacterial lipoarabinoman-
nan by the dendritic cell lectin DC-SIGN is an example of
an interaction with microbial carbohydrates [25]. The bind-
ing of the B-cell lectin CD22 to α2,6–linked Sia further
illustrates the importance of endogenous glycans in regu-
lating B-cell activation [26]. The oligosaccharide lacto-N-
fucopentaose III has been shown to induce the proliferation
of splenic B-cells and to stimulate the production of inter-
leukin-10 (IL-10) when added directly to splenic cells in
vitro [27]. The question as to whether milk oligosacchar-
ides interact with immune cells in the intestinal lumen or in
the bloodstream after absorption remains open for debate.
The detection of small amounts of milk oligosaccharides in
the urine of breastfed infants [14] suggests that these mo-
lecules can indeed interact with circulating leucocytes, but
this assumption has yet to be proven.
Considering the tremendous structural complexity of hu-
man milk oligosaccharides, the main challenge that exists
is in identifying the specific functions of individual milk
oligosaccharides. The multiple potential effects of milk oli-
gosaccharides on the intestinal microbiota and on the mu-
cosal immune system highlight the requirement for per-
forming in-vivo investigations. Rodents such as the mouse
lack the oligosaccharide diversity of human milk [28, 29],
but the availability of mouse knockout models for the genes
involved in milk oligosaccharide biosynthesis enables the
systematic analysis of these oligosaccharides. Accordingly,
our research group has applied sialyltransferase-knockout
mice to investigate the biological functions of the major
milk oligosaccharides Sia(α2,3)lactose (3SL) and
Sia(α2,6)lactose (6SL). The trisaccharides 3SL and 6SL
are produced by α2,3 sialyltransferase and α2,6 sialyltrans-
ferase, respectively, which transfer Sia to lactose through
distinct linkages yielding different conformations (fig. 4).
The impact of the exposure to these oligosaccharides dur-
ing lactation was addressed by feeding newborn mice with
either normal milk or milk deficient in the oligosaccharides
of interest. Interestingly, we found that mice fed on milk
lacking the oligosaccharide 3SL were more resistant as
adults to a form of chemically-induced colitis [29]. In con-
trast, the exposure to the structurally similar oligosacchar-
ide 6SL did not affect the development of colitis in the
applied model. The presence of 3SL in the maternal milk
influenced durably the composition of intestinal microbiota
in the nursed mice. For example, clostridial cluster IV bac-
teria of genus Ruminococcus were found only in mice ex-
posed to 3SL during lactation. The influence of intestinal
microbiota on the course of chemically induced colitis was
confirmed by reconstitution of germ-free mice with the
intestinal flora isolated from mice previously fed either
3SL-containing milk, or 3SL-deficient milk. Mice harbour-
ing microbiota including increased clostridial cluster IV
bacteria developed a more severe colitis than mice har-
bouring microbiota lacking clostridial cluster IV bacteria
[29]. These experiments demonstrated that the exposure to
specific milk oligosaccharides during lactation affects the
composition of the intestinal flora and maintains a durable
effect on the susceptibility to intestinal inflammation. The
question remains as to why a naturally occurring milk oli-
gosaccharide such as 3SL would worsen an inflammatory
response. This would indicate that some milk oligosacchar-
ides mediate proinflammatory functions, which is definit-
ively counterintuitive. A possible explanation for this para-
doxical situation emerged from our study of 3SL and 6SL
in the context of the innate immune system.
When supplementing mice orally with the milk oligosac-
charide 3SL in the course of our study, we observed in-
creased activation of intestinal CD11c+ dendritic cells [30].
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Dendritic cells are at the forefront of the immune system.
They sense the environment for antigens and trigger both
innate and adaptive immune responses. Dendritic cells ex-
press a broad range of pattern-recognition receptors such as
toll-like receptors (TLR) and lectins such as DC-SIGN and
sialic acid-binding immunoglobulin-type lectin-E (siglec-
E). In addition to presenting antigens to T-cells, dendritic
cells polarise adaptive responses through the production of
the tolerogenic cytokines IL-10 and transforming growth
factor-beta (TGFβ), or the proinflammatory cytokines IL-6,
IL-12, and tumour necrosis factor-alpha (TNFα). Dendritic
cells are known to recognise foreign bacterial carbohydrate
structures such as peptidoglycan and lipopolysaccharide
(LPS). In contrast, a stimulatory effect of milk oligosac-
charides on dendritic cells had not been reported before.
We did find that the stimulatory effect of 3SL on CD11c+
dendritic cells was dose-dependent and specific, since the
structurally related oligosaccharide 6SL had no effect. The
stimulation of CD11c+ dendritic cells by 3SL resulted in in-
creased expression of the activation markers CD80, CD86
and major histocompatibility complex-II (MHC-II). The
activation of intestinal dendritic cells by 3SL was observed
both by directly stimulating cells in vitro and in vivo after
oral supplementation of mice. The 3SL-mediated activa-
tion was abrogated when testing dendritic cells lacking the
adaptor protein MyD88, which is essential for the transduc-
tion of most TLR signals. Closer examination of the TLR
pathway revealed that 3SL recognition mainly involved
TLR4 [30], which is also required for LPS recognition [31].
The rationale for the proinflammatory effect of the milk
oligosaccharide 3SL may be related to the presence of
α2,3–linked Sia at the surface of several pathogenic bac-
teria, such as Campylobacter jejuni, Neisseria meningitides
and Haemophilus influenzae. For example, TLR4 is re-
quired on dendritic cells for the recognition of Campylob-
acter jejuni α2,3–sialylated lipo-oligosaccharides [32]. Ac-
cordingly, the exposure of intestinal dendritic cells to 3SL
during lactation may result in a priming of the infant in-
nate immunity, which contributes to the defence against
α2,3Sia-expressing bacteria. Whereas 3SL mediates proin-
flammatory signals via TLR4, other milk oligosaccharides
may interact with different carbohydrate-binding proteins
and possibly trigger suppressive signals. The siglec family,
for instance, dampens leucocyte activation upon binding
to sialylated ligands [26]. The exact effect of milk oli-
gosaccharides on immune cells can only be elucidated once
pure oligosaccharides become available in large amounts.
The technical complexity and considerable expenses linked
to the chemical synthesis of oligosaccharides have pre-
cluded the biological study of these compounds to date.
Fortunately, ingenious innovations in carbohydrate chem-
istry now enable the large scale production of oligosacchar-
ides [33] and thereby their investigation in vivo.
Whereas mouse models will further contribute to the func-
tional characterisation of milk oligosaccharides, the future
definitively lies in performing human studies. Milk oli-
gosaccharides are natural products and devoid of any tox-
icity, meaning that they can be tested as food additives.
Supplementation studies performed to date with unnatural
carbohydrates such as galacto-oligosaccharides and fructo-
oligosaccharide have displayed no adverse effects [34],
thus confirming the safety of oligosaccharides. The supple-
mentation of infant formula with naturally-occurring milk
oligosaccharides will certainly represent a main field of de-
velopment, but milk oligosaccharides should also be con-
sidered for applications in adults. Regimens including milk
oligosaccharides could contribute to the restoration of a
normal intestinal flora after chemotherapy and extended
antibiotic treatment. Furthermore, recent studies have
shown that intestinal microbiota influence the development
of obesity [35], atherosclerosis [36] and diabetes [37],
among other metabolic disorders. Along this line, it will be
interesting to address whether milk oligosaccharides may
be applied to influence intestinal microbiota durably in
adults and thereby delay or even prevent disease develop-
ment.
Got breast milk? The recent discoveries regarding the com-
plex interactions of milk oligosaccharides with intestinal
microbiota and the mucosal immune system have demon-
strated that breast milk provides much more than just nutri-
ents to infants. Breast milk is definitively the gold standard
for infant nutrition.
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Figures (large format)
Figure 1
Composition of breast milk and cow’s milk. (A) General molecular classes given in percent of total mass. (B) Percentage of main types of milk
proteins.
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Figure 2
Milk oligosaccharide biosynthesis. Oligosaccharides are represented by the symbolic nomenclature of the Functional Consortium for Glycomics
(see www.functionalglycomics.org/static/consortium/Nomenclature.shtml). The disaccharide lactose (in orange frame) is produced by the β1–4
galactosyltransferase / α-lactalbumin complex. Lactose is further modified by elongation with galactose(β1–4)N-acetylglucosamine
disaccharides and addition of fucose and sialic acid.
2FL = fucosyl(α1,2)lactose; 3FL = fucosyl(α1,3)lactose; 3SL = sialyl(α2,3)lactose; 6SL = sialyl(α2,6)lactose
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Figure 3
Relative amount of two complex milk oligosaccharides during lactation. The relative levels of the pentasaccharide lacto-N-fucopentaose drop
rapidly in the first week of lactation, whereas the relative levels of the heptasaccharide lacto-N-fucoseptaose raise in the first 2 weeks of
lactation. Oligosaccharides levels are compared with the constant levels of the milk tetrasaccharide lacto-N-tetraose. The oligosaccharide levels
shown were analysed in breast milk samples collected from a single mother over 3 weeks after childbirth.
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Figure 4
Structure of 3–sialyllactose and 6–sialyllactose. The three-dimensional structures point to the extended configuration of 3–sialyllactose and bent
configuration of 6–sialyllactose. The positions of the third and sixth C-atoms of galactose (Gal), to which sialic acid (Sia) is attached are marked
with the numbers 3 for 3–sialyllactose and 6 for 6–sialyllactose.
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